Autophagy inhibition overcomes sorafenib resistance in S45F‐mutated desmoid tumors

Abstract excerpt

BACKGROUND: Desmoid tumors (DTs) are rare and understudied fibroblastic lesions that are frequently recurrent and locally invasive. DT patients often experience chronic pain, organ dysfunction, decrease in quality of life, and even death. METHODS: Sorafenib has emerged as a promising therapeutic strategy, which has led to the first randomized phase 3 clinical trial devoted to DTs. Concurrently, we conducted a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Sarcoma Diagnosis and Treatment
• Share to Soft tissue tumor case studies
• Share to Soft tissue tumors and treatment